Otsuka Holdings Co., Ltd.
Stock Price Chart
2026/11/09 12:01 UpdatedPrice Trend
2026/11/09 12:01 UpdatedPrice & Trading Details
2026/11/09 12:01 UpdatedPRICE
TRADING
Analyst Recommendations 12 analysts
Updated 2026/11/01Earnings Calendar
Updated 2026/11/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/10/30 | ¥180.81 | ¥202.96 | +12.3% |
| 2026/07/31 | ¥162.71 | ¥222.76 | +36.9% |
| 2026/04/28 | ¥134.20 | ¥186.31 | +38.8% |
| 2026/02/12 | ¥74.42 | ¥124.25 | +67.0% |
Shareholder Composition
Updated 2026/11/01Top Mutual Funds / ETFs
Updated 2026/11/01Major Holders
Updated 2026/11/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
6.5M | +1.32% | |
|
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund
|
5.4M | -12.63% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
4.3M | +1.65% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
3.2M | +1.32% | |
|
iShares, Inc.-iShares MSCI Japan ETF
|
1.9M | +3.16% | |
|
Fidelity Concord Street Trust-Fidelity International Index Fund
|
1.6M | +0.80% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Aristotle Capital Management, LLC
|
1.1M | -7.80% | |
|
Paradigm Asset Management Company, LLC
|
20.0K | 0.00% | |
|
Pacer Advisors, Inc.
|
4.0K | -98.03% |
Dividend History
Updated 2026/11/08| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥100 | -28.6% |
| 2025 | ¥140 | +16.7% |
| 2024 | ¥120 | +9.1% |
| 2023 | ¥110 | +10.0% |
| 2022 | ¥100 | - |
Financial Performance
2026/11/08 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥1,498,276M | ¥1,737,998M | ¥2,018,568M | ¥2,329,861M |
| Gross Profit | ¥1,003,245M | ¥1,168,496M | ¥1,407,348M | ¥1,669,428M |
| Operating Income | ¥152,469M | ¥186,064M | ¥291,668M | ¥415,992M |
| Pretax Income | ¥168,478M | ¥179,017M | ¥149,178M | ¥344,645M |
| Net Income | ¥125,463M | ¥133,906M | ¥121,616M | ¥343,120M |
| EPS | ¥231.15 | ¥246.78 | ¥224.10 | ¥633.76 |
| Operating Margin | 10.18% | 10.71% | 14.45% | 17.85% |
| Balance Sheet | ||||
| Total Assets | ¥2,820,915M | ¥3,102,638M | ¥3,361,244M | ¥3,739,251M |
| Total Equity | ¥2,010,994M | ¥2,225,255M | ¥2,393,683M | ¥2,733,580M |
| Total Liabilities | ¥809,921M | ¥877,383M | ¥967,561M | ¥1,005,671M |
| Cash | ¥410,684M | ¥471,634M | ¥513,341M | ¥426,173M |
| Interest-bearing Debt | ¥212,453M | ¥194,161M | ¥214,187M | ¥189,383M |
| Equity Ratio | 71.29% | 71.72% | 71.21% | 73.11% |
| D/E Ratio | 0.11 | 0.09 | 0.09 | 0.07 |
| Cash Flow | ||||
| Operating CF | ¥228,864M | ¥211,848M | ¥283,232M | ¥354,638M |
| Investing CF | -¥95,288M | -¥81,575M | -¥190,538M | -¥265,793M |
| Financing CF | -¥95,844M | -¥95,474M | -¥60,260M | -¥189,367M |
| Free CF | ¥115,712M | ¥104,061M | ¥168,559M | ¥225,276M |
| Efficiency | ||||
| ROE | 6.24% | 6.02% | 5.08% | 12.55% |
| ROA | 4.45% | 4.32% | 3.62% | 9.18% |
Latest IR Information
-
Notice Regarding Transition to a Company with an Audit and Supervisory Committee
Resolved to transition from a company with a Board of Corporate Auditors to a company with an Audit and Supervisory Committee, contingent on approval at the Ordinary General Meeting of Shareholders to be held in March 2027. The Nomination and...
Read more -
Notice Regarding Results of Treasury Stock Acquisition, Completion of Acquisition and Number of Shares Cancelled
Total amount of treasury stock acquisitions from February to October 2026: 49,994,398,554 yen; number of shares acquired: 4,537,700 shares; acquisition period: 2026/2/16–2026/10/28. Additionally, previously acquired shares totaling 2,958,635,000 yen and 254,200 shares were acquired. Cancellation date is scheduled for 2026/12/11,...
Read more -
Otsuka Holdings Co., Ltd. Third Quarter Financial Summary [IFRS] (Consolidated)
Revenue was 2,042,439 hundred million yen, up 12.3% year-over-year for the same quarter. Segment profit was 436,884 hundred million yen, operating income was 423,733 hundred million yen, and quarter profit was 326,463 hundred million yen. Full-year forecasts were revised, and...
Read more -
Presentation of Final Phase 3 Results for VOYXACT® (sibepremlimab) for IgA Nephropathy at ASN / sBLA Submission to FDA
VOYXACT (sibepremlimab) for IgA nephropathy: final Phase 3 analysis presented at ASN Kidney Week 2026. Demonstrated renal function stabilization and a large reduction in risk of composite renal events (97.1%); safety profile comparable to placebo. sBLA submission to the FDA...
Read more -
Completion of Rolling Submission of sBLA for IgA Nephropathy Treatment VOYXACT® (Cibeplernimab) in the United States
Announced completion of the rolling submission of the US sBLA for VOYXACT. Stated there is currently no change to the consolidated earnings forecast for the fiscal year ending December 2026 and emphasized positioning VOYXACT as a long-term growth driver.
Read more
Latest News (5 items)
-
Average Analyst Rating: buy
Average Target Price: ¥14,631
Rating Score: 1.77 (Based on 12 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Otsuka Holdings Co., Ltd. engages in the pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. It develops pharmaceutical products in the fields of psychiatry, neurology, oncology, cardiovascular and renal system, autoimmune space digestive system, ophthalmology, and diagnostics, as well as intravenous solutions and medical devices. It also provides clinical testing, medical equipment and tools, food products, cosmetics, functional food products, chemical products, soft drinks, beverages, analytical and measurement equipment, nutritional products, vehicle headlight testers, synthetic resin molded products, paper products, quasi-drugs, household products, and packaging materials and electronic parts. In addition, it offers IT solutions; adhesive tapes; flaky titanate and compounds; infusion and clinical nutrition products; hydrazine; plant-based food products; reinsurance underwriting services; wine; stable isotopes; food supplements; software and services for management of mental healthcare systems; anticancer drugs; terracess; bio-pesticides; dietetic food products; spring and mineral water; and polyolefin foams. Further, it engages in the warehousing and transport, medical device operational management, shared service, environmental health management, and venture capital and incubation businesses; rental of medical devices and related products; purchase and sale of agricultural products; import and export trading business; tuberculosis research and development activities; rental of space and office businesses; manufacturing and development of xenotransplantation products; and processing and marketing of functional films, as well as planning, design, production, and construction of ceramic boards and arts, ceramic walls, reliefs, terracotta, ceramic OT and portraits, and ceramic sign boards; and operation of travel agency, and Hotel Ridge and California Table. The company was founded in 1921 and is headquartered in Chiyoda, Japan.